Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 16/20 | 0.44 |
| ▸ | BCL2 | P10415 | 5/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.42 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7971998 | 0.90 | MCL1 (0.45) | MCL1BCL2BCL2L1GPR119UCHL1 | |
| SCHEMBL6847596 | 0.90 | MCL1 (0.45) | MCL1BCL2BCL2L1GPR119UCHL1 | |
| SCHEMBL7971995 | 0.90 | MCL1 (0.45) | MCL1BCL2BCL2L1GPR119UCHL1 | |
| SCHEMBL6847593 | 0.90 | MCL1 (0.45) | MCL1BCL2BCL2L1GPR119UCHL1 | |
| SCHEMBL2408809 | 0.89 | P2RX3 (0.41) | MCL1BCL2BCL2L1P2RX3NR1H2 | |
| SCHEMBL2408811 | 0.89 | P2RX3 (0.41) | MCL1BCL2BCL2L1P2RX3NR1H2 | |
| SCHEMBL30170377 | 0.87 | P2RX3 (0.41) | MCL1BCL2BCL2L1P2RX3NR1H2 | |
| SCHEMBL27017548 | 0.87 | P2RX3 (0.41) | MCL1BCL2BCL2L1P2RX3NR1H2 | |
| SCHEMBL24739556 | 0.83 | NR1H2 (0.43) | MCL1P2RX3NR1H2NR1H3GPR119 | |
| SCHEMBL13481242 | 0.83 | NR1H2 (0.43) | MCL1P2RX3NR1H2NR1H3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| EP-4551569-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4366831-A1 | ANTI-VIRAL COMPOUNDS | Aligos Therapeutics, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-04-04 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-01-18 | — | — | US | disclosed |
| US-11851422-B2 | Anti-viral compounds | ALIGOS THERAPEUTICS, INC. | 2023-12-26 | — | — | US | disclosed |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-03-23 | — | — | US | disclosed |
| WO-2023283256-A1 | ANTI-VIRAL COMPOUNDS | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885BCL2 3829/4885BCL2L1 3193/4885 |
| US-20230093249-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885BCL2 3829/4885BCL2L1 3193/4885 |
| US-11851422-B2 | Anti-viral compounds | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885BCL2 3829/4885BCL2L1 3193/4885 |
| US-20240018126-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885BCL2 3829/4885BCL2L1 3193/4885 |
| US-20240109871-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | MCL1 1723/4885BCL2 3829/4885BCL2L1 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.